160 results
6-K
EX-99.3
GLPG
Galapagos NV
11 May 21
Current report (foreign)
2:10pm
as of February 4, 2020 (as so assigned and amended, the “A&R Collaboration Agreement”), pursuant to which, among other things, Galapagos is responsible … is responsible for Commercializing the Licensed Product in all other countries in the Galapagos Territory and in the Gilead Territory; and
WHEREAS
6-K
EX-99.1
GLPG
Galapagos NV
28 Mar 22
Jyseleca® approved in Japan for ulcerative colitis
1:50pm
Japan will hold the marketing authorization of Jyseleca in Japan and will be responsible for product supply. Eisai will be responsible for product … are collaborative partners in the global development and commercialization of filgotinib. Galapagos is responsible for the commercialization of filgotinib in Europe
6-K
EX-99.1
GLPG
Galapagos NV
6 Oct 21
Galapagos announces completion of patient enrollment for DIVERSITY Phase 3 study with filgotinib in Crohn’s Disease
6:00am
responsibility for the DIVERSITY clinical study. From April 1, 2022, Galapagos will also be solely responsible for all development costs … to 10.5% of net sales in Europe. These royalties are payable as of 2024. Gilead remains responsible for commercial activities outside of Europe.
About
6-K
EX-99.3
GLPG
Galapagos NV
29 Aug 19
Gilead and Galapagos Complete Closing of Their Transformative Research and Development Collaboration
4:44pm
existing under the License and Collaboration Agreement, Galapagos will be responsible for Commercialization activities for the Benelux Countries … . The Gilead Alliance Manager will be responsible for preparing reasonably detailed written minutes of all JSC meetings
Amended and Restated License
6-K
EX-99.6
GLPG
Galapagos NV
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
assumptions.
Responsibilities of administrative body for the drafting of the annual accounts
The administrative body is responsible … , whether due to fraud or error.
In preparing the annual accounts, the administrative body is responsible for assessing the Company’s ability to continue
6-K
EX-99.1
a7whi7
24 Mar 22
Galapagos publishes 2021 annual report and announces Biographies of proposed new board members
8:13pm
6-K
EX-99.2
ch90o y2z5yfbjv5cs
11 Apr 22
Current report (foreign)
5:14pm
6-K
EX-99.6
3qs3g2ai87ksa44r2
24 Mar 22
Galapagos publishes 2021 annual report and announces Biographies of proposed new board members
8:13pm
6-K
EX-99.2
2stu68f 0rtdslimn0so
29 Aug 19
Gilead and Galapagos Complete Closing of Their Transformative Research and Development Collaboration
4:44pm
6-K
EX-99.8
46sza60iez1y2 qi0m
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
6-K
EX-99.1
l0gixo
25 Sep 20
Jyseleca® (filgotinib) approved in Japan for rheumatoid arthritis
6:05am
6-K
EX-99.1
512tijjq4tiy0 1avrtl
15 Oct 20
Galapagos and Servier report topline results for ROCCELLA Phase 2 clinical trial with GLPG1972/S201086 in knee osteoarthritis patients
5:27pm
6-K
EX-99.1
00l2wh
23 Apr 21
Current report (foreign)
6:05am
6-K
EX-99.1
v6q45n23j71rone0cp
16 Apr 20
Galapagos and Ryvu announce research collaboration
6:05am
6-K
EX-99.1
9mejcj77x4ud
17 Nov 21
Jyseleca®▼(filgotinib) approved in the European Union for the treatment of ulcerative colitis
6:00am
DRS/A
EX-10
7uw6qo4wtzak7fwi49
4 Mar 15
Draft registration statement (amended)
12:00am